Cancer Biology & Medicine

Papers
(The H4-Index of Cancer Biology & Medicine is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Eliminating cervical cancer: a global health imperative for women225
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy129
The Warburg effect drives dedifferentiation through epigenetic reprogramming69
A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer57
Artificial intelligence in breast cancer: applications and advancements56
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity53
Early-onset gastric cancer global burden profile, trends, and contributors52
Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma47
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance46
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer45
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up42
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives37
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer37
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies36
Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications33
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer33
<italic>Bifidobacterium animalis</italic> suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8<sup>&#x002B;</sup> T cells33
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente31
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis30
Lung cancer mortality trends in China from 2013 to 2021 and projections to 203029
Immune checkpoint inhibitors: breakthroughs in cancer treatment28
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment28
Biological mechanism and immune response of MHC-II expression in tumor cells27
Cancer stem cells: a target for overcoming therapeutic resistance and relapse27
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC27
Chinese expert consensus on additional surgery following endoscopic resection for early colorectal cancer (2025 edition)25
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis25
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer25
0.050121068954468